SPY423.35+0.24 0.06%
DIA339.18-0.27 -0.08%
IXIC14,292.48+39.21 0.28%

Fulcrum Obtains FDA Fast Track Status for Losmapimod in Facioscapulohumeral Muscular Dystrophy

05/12/2021 04:38

08:36 AM EDT, 05/12/2021 (MT Newswires) -- Fulcrum Therapeutics (FULC) on Wednesday said that the US Food and Drug Administration has granted fast track status to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy.

Full data from a phase 2b trial of losmapimod in patients with facioscapulohumeral muscular dystrophy are on track to be reported at the virtual FSHD International Research Congress taking place in late June, the company said.

Price: 10.66, Change: +0.22, Percent Change: +2.11